TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Buy" by Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has received a consensus rating of "Buy" from the five research firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.80.

A number of research firms recently commented on TCRX. Wall Street Zen lowered TScan Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Morgan Stanley reiterated an "overweight" rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Friday, March 14th. HC Wainwright cut their target price on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, May 6th.

TScan Therapeutics Stock Down 1.1%

Shares of TScan Therapeutics stock traded down $0.02 during trading hours on Wednesday, reaching $1.82. The company's stock had a trading volume of 222,989 shares, compared to its average volume of 409,645. The company has a market capitalization of $103.00 million, a P/E ratio of -1.67 and a beta of 0.97. The stock's fifty day simple moving average is $1.49 and its two-hundred day simple moving average is $1.84. TScan Therapeutics has a one year low of $1.02 and a one year high of $7.89. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.55 and a current ratio of 8.55.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. On average, research analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

Insider Buying and Selling at TScan Therapeutics

In other news, major shareholder Lynx1 Capital Management Lp acquired 1,388,794 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average price of $1.20 per share, for a total transaction of $1,666,552.80. Following the completion of the purchase, the insider owned 6,746,141 shares in the company, valued at approximately $8,095,369.20. This trade represents a 25.92% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BVF Inc. IL raised its position in shares of TScan Therapeutics by 63.6% in the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock valued at $6,747,000 after purchasing an additional 1,900,000 shares during the period. Checkpoint Capital L.P. grew its holdings in TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock valued at $2,784,000 after buying an additional 261,663 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after purchasing an additional 145,731 shares in the last quarter. Lynx1 Capital Management LP boosted its holdings in TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock valued at $16,286,000 after purchasing an additional 132,747 shares during the period. Finally, Tang Capital Management LLC purchased a new position in shares of TScan Therapeutics during the 4th quarter valued at $358,000. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.